This activity provides an in-depth exploration of advanced quantitative imaging techniques for personalized radiotherapy, focusing on addressing barriers to clinical implementation and improving the management of lung toxicity.

Radiopharmaceutical therapies (RPTs) are increasingly utilized for treatment of prostate, neuroendocrine, thyroid and other cancers.

This activity discusses the use of PSMA PET for staging in high-risk prostate cancer. This includes when to order a PSMA PET, how to interpret it, common pitfalls and controversies of the scans.

Using a case-based approach, this activity discusses challenging scenarios that are encountered in the management of women with uterine cancer.

This activity includes a panel of experts from breast radiation oncology, surgical oncology, medical oncology, and pathology to discuss the following rare histologies/breast cancer presentations: 1) Pleomorphic LCIS- diagnosis and differential (path) appropriate margin width (surgeon), role of ad

This activity reviews the various oligometastatic states, existing and upcoming data supporting radiation in appropriately selected patients, intersection of radiation with systemic therapy, and practical applications of radiation treatment delivery with a focus on stereotactic ablative radiation

This activity presents challenging clinical scenarios arising in the management of patients with gastrointestinal malignancies.

This activity provides an opportunity to understand the key steps in the process of care for SBRT treatment of liver (primary and metastases), focusing on patient selection, imaging, simulation, treatment planning and image guidance, and discuss challenges in motion management and delivery.

This activity focuses on difficult cases in the use of lung SBRT. It includes a set of challenging cases followed by a short didactic session on each challenging topic. The cases/topics include: 1) SBRT for a large (>5 cm) primary, node negative tumor.

A session of challenging cases in lymphoma with a panel of expert radiation oncologists, including one in private practice, and a lymphoma medical oncologist is presented: (1) Refractory CNS lymphoma – primary or secondary, with plans for, or having completed CAR T-cell therapy.